Trial · NCT00391443
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Placebo | month 4 (122 days) | 10 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Bosentan | month 4 (122 days) | 18 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Placebo | month 8 (244 days) | 22 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Bosentan | month 8 (244 days) | 40 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Placebo | month12 (366 days) | 43 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Bosentan | month12 (366 days) | 74 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Placebo | month 18 (549 days) | 74 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Bosentan | month 18 (549 days) | 117 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Placebo | month 24 (732 days) | 88 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Bosentan | month 24 (732 days) | 145 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Placebo | month 30 (915 days) | 94 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Bosentan | month 30 (915 days) | 156 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Placebo | month 36 (1098 days) | 94 | participants with event | |
| Time to Occurrence of Disease Worsening or Death up to End of Study. | Bosentan | month 36 (1098 days) | 158 | participants with event | |
| Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year. | Placebo | 23.9 | 95% Confidence Interval 18.3 to 30.3 | percentage of participants with event | |
| Percentage of Patients Who Experienced Either Disease Worsening or Death at 1 Year. | Bosentan | 19.9 | 95% Confidence Interval 16.1 to 24.1 | percentage of participants with event |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00391443/results